Berlin, May 18, 2026 — The World Health Organization (WHO) has declared a Public Health Emergency of International Concern (PHEIC) following a deadly Ebola outbreak in the Democratic Republic of Congo (DRC) and Uganda, marking the first such declaration for the disease since 2019. The announcement comes as health authorities confirm over 100 cases and 45 deaths across the two countries, with the virus spreading faster than previous outbreaks. The strain identified is Ebola Bundibugyo, a variant for which no approved vaccine currently exists, raising urgent concerns about containment and global preparedness.
In a press briefing on May 17, WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the “extraordinary circumstances” justifying the PHEIC declaration, noting the outbreak’s rapid transmission, geographic spread, and the absence of a licensed vaccine for this specific strain. “This is a critical moment for global health,” Dr. Tedros stated. “We must act decisively to prevent further spread and protect vulnerable communities.” The declaration triggers heightened international cooperation, resource mobilization, and travel advisories.
The outbreak began in North Kivu province, DRC, in early April 2026, with initial cases linked to a funeral ceremony where traditional burial practices facilitated transmission. By May 10, Uganda confirmed its first cases in the Mbarara district, just 30 kilometers from the DRC border, prompting immediate cross-border containment efforts. Health officials warn that the virus’s 21-day incubation period and high fatality rate—historically between 40% and 70%—pose significant challenges. Unlike the more common Ebola Sudan and Ebola Zaire strains, Bundibugyo has no approved vaccine, complicating response strategies.
Why This Outbreak Demands Global Attention
The PHEIC declaration is reserved for events that constitute a serious, sudden, unusual, or unexpected public health risk to other countries. Key factors in this decision include:
- Rapid geographic expansion: Cases now span three provinces in DRC (North Kivu, Ituri, and South Kivu) and two districts in Uganda, with potential for further spread given porous borders and active conflict zones.
- Lack of vaccine efficacy: The Ervebo vaccine, effective against Ebola Zaire, is not authorized for Bundibugyo. Experimental treatments like mAb114 and REGN-EB3 are being evaluated but remain unproven for this strain.
- Weak healthcare infrastructure: The DRC’s health system, already strained by decades of conflict, faces shortages of personal protective equipment (PPE), trained staff, and laboratory capacity.
- Risk of international spread: While the WHO assesses the global risk as moderate, the outbreak’s proximity to major hubs like Kampala (Uganda) and Goma (DRC) raises concerns about air travel and cross-border movement.
In response, the WHO has activated its Emergency Operations Center and deployed a 100-person international team to support local efforts. The African Union and Doctors Without Borders (MSF) have also mobilized resources, including mobile laboratories and treatment centers. The European Centre for Disease Prevention and Control (ECDC) has issued travel health notices, advising against non-essential travel to affected regions.
The Bundibugyo Strain: What Makes It Different?
Ebola Bundibugyo, first identified in 2007 in Uganda, is one of six known Ebola virus species. Unlike the more virulent Ebola Zaire (responsible for the 2014–2016 West Africa outbreak), Bundibugyo has historically caused smaller, localized outbreaks with lower transmission rates. However, this latest surge has defied expectations:
- Transmission dynamics: Early data suggests community transmission (person-to-person spread outside healthcare settings) is driving the outbreak, likely due to funeral rituals and close-contact care practices.
- Symptom presentation: Initial symptoms—fever, fatigue, muscle pain, and vomiting—mirror malaria and other tropical diseases, delaying diagnosis in regions with limited testing.
- Diagnostic challenges: PCR testing for Bundibugyo requires specialized labs, many of which are non-operational in conflict zones.
Dr. Jean Kaseya, DRC’s Health Minister, warned during a joint press conference with Ugandan officials that “misinformation and stigma are as dangerous as the virus itself.” Local communities in some areas have rejected treatment centers, fearing abandonment or forced vaccination—a pattern seen in past outbreaks.
Global Response: What’s Being Done?
Since the PHEIC declaration, several critical actions have been taken:
- Cross-border coordination: DRC and Uganda have established a joint incident command center to synchronize surveillance, contact tracing, and vaccination strategies (where applicable).
- Airport screenings: Kenya, Rwanda, and South Sudan have enhanced thermal scanning and health declarations for travelers from high-risk areas.
- Research acceleration: The WHO Solidarity Trial is expanding to test experimental treatments for Bundibugyo, with preliminary results expected by June 2026.
- Public health messaging: Campaigns in local languages are promoting hand hygiene, safe burial practices, and avoidance of bush meat—a known zoonotic reservoir for Ebola.
However, challenges remain. The ongoing conflict in eastern DRC, including attacks on healthcare workers by armed groups, has disrupted response efforts. The United Nations has condemned these incidents, calling for “immediate protection for medical personnel” under international law.
Assessing the Risk: What Does This Mean for the Rest of the World?
The WHO’s risk assessment for regions outside Africa remains low to moderate, but health officials caution that air travel and globalized trade could accelerate spread if containment fails. Key considerations include:
- Vaccine stockpiles: The 250,000-dose global stockpile of Ervebo is not applicable to Bundibugyo, though some doses may be repurposed for clinical trials.
- Laboratory capacity: The WHO Collaborating Centre for Arboviruses and Hemorrhagic Fevers in Senegal is the only facility in Africa with Bundibugyo diagnostic capability.
- Economic impact: The DRC’s copper and cobalt mining sector, critical for global electronics supply chains, could face disruptions if the outbreak worsens.
In Europe, health authorities are monitoring the situation closely. The European Commission’s Health Security Committee met on May 16 to review border measures and stockpile readiness. Spain’s Ministry of Health has reiterated that the risk to its territory is “particularly low”, but is preparing rapid response teams for potential cases.
What You Need to Know: FAQ
Q: Can Ebola Bundibugyo spread outside Africa?
A: While the risk is currently low, the virus can spread through direct contact with bodily fluids of infected individuals. The WHO advises against non-essential travel to affected regions and encourages vigilance for symptoms (fever, severe headache, muscle pain) within 21 days of return.
Q: Is there a vaccine for this strain?
A: No. The Ervebo vaccine (approved for Ebola Zaire) is not effective against Bundibugyo. Researchers are testing modified versions of the vaccine and other experimental treatments, but none are currently licensed.
Q: How can I protect myself if I’m traveling to the region?
A: Follow WHO travel advice:
- Avoid contact with sick or deceased individuals.
- Use hand sanitizer and wash hands frequently.
- Avoid bush meat and uncooked food.
- Seek medical care immediately if symptoms develop.
Q: Why wasn’t this declared earlier?
A: The WHO follows a graduated response. The outbreak was initially contained, but its acceleration in May 2026—including cross-border spread—triggered the PHEIC declaration. The absence of a vaccine and conflict-related barriers were decisive factors.
Looking Ahead: The Next Critical Steps
The next 30 days are critical for containing the outbreak. Key milestones include:
- May 20–25, 2026: WHO and partners aim to double the number of treatment beds in DRC and Uganda, targeting 500 beds total.
- May 30, 2026: Deadline for African Union emergency funding request ($100 million) to scale up response.
- June 2026: Expected preliminary results from clinical trials of experimental treatments.
- Ongoing: Weekly WHO risk assessments and updates on https://www.who.int/emergencies/disease-outbreak-news.
Dr. Matshidiso Moeti, WHO Regional Director for Africa, urged global solidarity: “This outbreak is a test of our collective preparedness. We must act with urgency, precision, and compassion.” She highlighted the need for funding, medical supplies, and protection for frontline workers.
For real-time updates, visit the WHO Ebola situation room (link) or your local health authority’s travel advisories. If you have concerns about travel or symptoms, consult a healthcare provider.
Share this article to raise awareness, and join the conversation below: What questions do you have about the outbreak or global health preparedness?